These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7926260)

  • 21. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
    Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
    Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens.
    Kuil CW; Mulder E
    Endocrinology; 1996 May; 137(5):1870-7. PubMed ID: 8612526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
    de Jesus Cortez F; Nguyen P; Truillet C; Tian B; Kuchenbecker KM; Evans MJ; Webb P; Jacobson MP; Fletterick RJ; England PM
    ACS Chem Biol; 2017 Dec; 12(12):2934-2939. PubMed ID: 28981251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
    Song LN; Coghlan M; Gelmann EP
    Mol Endocrinol; 2004 Jan; 18(1):70-85. PubMed ID: 14593076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular determinants of resistance to antiandrogen therapy.
    Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
    Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure.
    Couette B; Fagart J; Jalaguier S; Lombes M; Souque A; Rafestin-Oblin ME
    Biochem J; 1996 Apr; 315 ( Pt 2)(Pt 2):421-7. PubMed ID: 8615809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen and antiandrogen receptor binding.
    Jänne OA; Bardin CW
    Annu Rev Physiol; 1984; 46():107-18. PubMed ID: 6370101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Domain functions of the androgen receptor.
    Simental JA; Sar M; Wilson EM
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):37-41. PubMed ID: 1525065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiandrogen action in the development of androgen insensitivity in S115 mouse mammary tumour cells.
    Darbre PD; Chadwick J; Edwards H; Carrick N; Perachiotti A
    J Steroid Biochem Mol Biol; 1993 Sep; 46(3):299-307. PubMed ID: 9831478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
    Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
    Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
    Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of mutant androgen receptors by flutamide.
    Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
    Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited proteolysis for assaying ligand binding affinities of nuclear receptors.
    Benkoussa M; Nominé B; Mouchon A; Lefebvre B; Bernardon JM; Formstecher P; Lefebvre P
    Recept Signal Transduct; 1997; 7(4):257-67. PubMed ID: 9633826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.